Aesica
Aesica’s High Capacity Manufacturing facility has been validated for commercial production; $45 million (€32.4/£27 million) has been invested at its Queenborough, UK, site.
With the completion of this new facility, Aesica has expanded the commercial production of a solid dose medication used in treating one of the world’s most common lifestyle diseases — Type 2 diabetes in adults. The solid dose product has global sales and is set for worldwide export.
The purpose built facility is capable of producing in excess of 1 billion tablets per annum and, designed with future expansion in mind, it is expected the facility will more than double its current capacity to produce over 2.5 billion tablets a year on expansion.
The facility provides a 929 m2 expansion to the existing Queenborough site and has a dedicated workforce of 55 technicians, with future expansion plans increasing the staffing level to more than 100.
The new facility is an advanced unit that contains highly technical and specialist equipment including spray granulators, coaters, tablet presses, powder handling systems and large capacity blenders.
Dr. Robert Hardy, CEO of Aesica Pharmaceuticals, commented: “The validation of this facility for commercial production is a major milestone for the company and brings to fruition what has been a significant investment. Aesica is already a major exporter of finished dose products and the investment in this facility reflects the continued growth in export demand. This state-of-the-art facility will allow us to manufacture a high quality product used to treat one of the world’s most prevalent diseases and has the capability to double its capacity in the future, representing an expanding revenue stream for Aesica.”
Aesica Pharmaceuticals Ltd, www.aesica-pharma.com.
